Pawar Sachin, Lim Hyun J, Gill Matthew, Smith Timothy L, Merati Albert, Toohill Robert J, Loehrl Todd A
Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
Am J Rhinol. 2007 Nov-Dec;21(6):695-701. doi: 10.2500/ajr.2007.21.3098.
Patients commonly present with complaints of postnasal drainage (PND) without objective evidence to support a sinonasal or infectious etiology. PND has been attributed to extra-esophageal reflux (EER), and an empiric trial of antireflux medication often is used to treat PND and associated symptoms. This study was performed to (1) evaluate the relationship between symptoms of EER and PND and (2) assess the efficacy of proton pump inhibitors (PPIs) in the management of PND.
Patients with a chief complaint of PND without objective evidence of sinonasal inflammatory disease were enrolled in a prospective, double-blinded, randomized placebo-controlled trial using rabeprazole, 20 mg, orally twice daily or placebo for 90 days. Subjects completed two-site 24-hour pharyngeal pH probe monitoring before treatment. Outcome measures included pre- and posttreatment visual analog scales for PND symptoms, reflux symptom index, and reflux finding score (RFS).
Forty-seven patients were enrolled (mean age, 55 years)-21 patients in the PPI group and 26 in the placebo group. Fifty-six percent of subjects had pH probe confirmed EER using a cutoff of pH < 5.0. Baseline symptom measures between subjects with and without EER were not different. Compared with placebo, subjects receiving rabeprazole reported significant reduction in PND frequency (p = 0.0180), hoarseness (p = 0.0164), and chronic cough (p = 0.0204). The RFS decreased slightly in the placebo group (p = 0.1490) whereas it increased slightly in the PPI group (p = 0.5235). This difference between groups was significant (p = 0.0272).
Although 50% of subjects had evidence of EER, there was no difference in baseline symptoms between subjects with and without. Our findings support the potential benefit of PPI therapy for reducing PND frequency, hoarseness, and chronic cough, and confirm a placebo effect for other laryngopharyngeal reflux symptoms. The effect on laryngeal findings is mixed and patients may experience symptomatic improvement before changes in laryngoscopic appearance.
患者常主诉有鼻后滴漏(PND),但缺乏支持鼻窦或感染病因的客观证据。PND被认为与食管外反流(EER)有关,抗反流药物的经验性试验常被用于治疗PND及相关症状。本研究旨在(1)评估EER症状与PND之间的关系,以及(2)评估质子泵抑制剂(PPI)治疗PND的疗效。
以PND为主诉且无鼻窦炎性疾病客观证据的患者被纳入一项前瞻性、双盲、随机安慰剂对照试验,使用雷贝拉唑,20mg,口服,每日两次,或安慰剂,为期90天。受试者在治疗前完成双位点24小时咽部pH探头监测。观察指标包括治疗前后PND症状的视觉模拟量表、反流症状指数和反流发现评分(RFS)。
共纳入47例患者(平均年龄55岁)——PPI组21例,安慰剂组26例。56%的受试者经pH探头证实存在EER,pH阈值<5.0。有EER和无EER受试者的基线症状指标无差异。与安慰剂相比,接受雷贝拉唑治疗的受试者PND频率(p = 0.0180)、声音嘶哑(p = 0.0164)和慢性咳嗽(p = 0.0204)显著降低。安慰剂组RFS略有下降(p = 0.1490),而PPI组略有上升(p = 0.5235)。两组间差异有统计学意义(p = 0.0272)。
尽管50%的受试者有EER证据,但有EER和无EER受试者的基线症状无差异。我们的研究结果支持PPI治疗在降低PND频率、声音嘶哑和慢性咳嗽方面的潜在益处,并证实了其他咽喉反流症状的安慰剂效应。对喉部表现的影响不一,患者可能在喉镜外观改变之前出现症状改善。